Carlos Jimenez-Cortegana
Overview
Explore the profile of Carlos Jimenez-Cortegana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hontecillas-Prieto L, Garcia-Dominguez D, Jimenez-Cortegana C, Nogales-Fernandez E, Palazon-Carrion N, Garcia-Sancho A, et al.
Cancer Metab
. 2025 Mar;
13(1):12.
PMID: 40038834
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma worldwide and is characterized by its heterogeneity. Although first-line therapy improves survival outcomes for DLBCL patients,...
2.
Marhold M, Vaz Batista M, Blancas I, Morales C, Saura-Manich C, Saavedra C, et al.
Future Oncol
. 2025 Feb;
:1-9.
PMID: 40018758
NCT06048718 (clinicaltrials.gov); 2023 -506,702-39-00 (EudraCT number).
3.
Fernandez-Castillejo S, Badia J, de la Cruz-Merino L, Garcia-Sancho A, Carnicero-Gonzalez F, Palazon-Carrion N, et al.
Cancers (Basel)
. 2025 Feb;
17(3).
PMID: 39941898
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for high-dose chemotherapy have limited treatment options and poor life expectancy. The purpose of this study...
4.
Buque A, Bloy N, Petroni G, Jimenez-Cortegana C, Sato A, Iribarren C, et al.
J Natl Cancer Inst
. 2024 Dec;
PMID: 39661487
Background: Hormone receptor (HR)+ breast cancer is poorly responsive to immune checkpoint inhibitors (ICIs). In some settings, radiation therapy (RT) has been shown to mediate immunostimulatory effects and promote ICI...
5.
Flores-Campos R, Garcia-Dominguez D, Hontecillas-Prieto L, Jimenez-Cortegana C, de la Cruz-Merino L, Sanchez-Margalet V
Methods Cell Biol
. 2024 Nov;
190:1-10.
PMID: 39515873
Myeloid-derived suppressor cells (MDSCs) encompass a diverse population of immature myeloid cells categorized into granulocytic and monocytic groups. These cells exert immune-suppressive functions within the tumor microenvironment, primarily influenced by...
6.
Jimenez-Cortegana C, Sanchez-Jimenez F, de la Cruz-Merino L, Sanchez-Margalet V
Int J Mol Med
. 2024 Oct;
55(1).
PMID: 39450529
Src‑associated in mitosis 68 kDa protein (Sam68) is a protein encoded by the heteronuclear ribonucleoprotein particle K homology (KH) single domain‑containing, RNA‑binding, signal transduction‑associated protein 1 (known as ) gene...
7.
Perez-Pelaez B, Jimenez-Cortegana C, de la Cruz-Merino L, Sanchez-Margalet V
Curr Issues Mol Biol
. 2024 Sep;
46(9):9286-9297.
PMID: 39329901
Myeloid-derived suppressor cells (MDSCs) are immature cells with an immunosuppressive function. MDSCs have been related to inflammation in many settings, including infections, transplantation, obesity, aging, or cancer. In oncological settings,...
8.
Jimenez-Cortegana C, Lopez-Enriquez S, Alba G, Santa-Maria C, Martin-Nunez G, Moreno-Ruiz F, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062791
Obesity is frequently accompanied by non-alcoholic fatty liver disease (NAFLD). These two diseases are associated with altered lipid metabolism, in which reverse cholesterol transport (LXRα/ABCA1/ABCG1) and leptin response (leptin receptor...
9.
Jimenez-Cortegana C, Gutierrez-Garcia C, Sanchez-Jimenez F, Vilarino-Garcia T, Flores-Campos R, Perez-Perez A, et al.
Int J Oncol
. 2024 Jun;
65(2).
PMID: 38940351
Obesity is a chronic disease caused by the accumulation of excessive adipose tissue. This disorder is characterized by chronic low‑grade inflammation, which promotes the release of proinflammatory mediators, including cytokines,...
10.
Hontecillas-Prieto L, Garcia-Dominguez D, Palazon-Carrion N, Garcia-Sancho A, Nogales-Fernandez E, Jimenez-Cortegana C, et al.
Front Immunol
. 2024 Mar;
15:1293931.
PMID: 38469299
Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in...